ClinicalTrials.gg
RecruitingNCT07668557ICG415-AML-01Updated Jun 25, 2026

Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1 interventional study of Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide in Acute Myeloid Leukemia (AML), sponsored by iCell Gene Therapeutics. Recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by iCell Gene Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 264 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
349th of 433
18 · median 50
Started
2026
with 55 others
Phase 1
121 of 473
69 open now
Primary completion
2028-07
later than 245 of 288 live
Registered
452nd of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 349th largest by planned enrollment of the 433 interventional ones that give a count, is one of 56 that started in 2026, is one of 121 in phase 1, reaches primary completion later than 245 of the 288 other live ones, and was the 452nd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

264 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

258 more — sign in →

All 264 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This single-arm, open-label phase I trial evaluates the safety and tolerability of ICG415, autologous CAR-T cells targeting CD33 and CLL1, in patients with relapsed or refractory acute myeloid leukemia (AML). Subjects receive lymphodepleting chemotherapy followed by autologous CAR-T infusion. The primary goal is to assess safety and preliminary anti-leukemic efficacy in patients failing standard AML therapies.

Read the detailed description

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with limited treatment options for patients who are relapsed or refractory (R/R) to standard therapies. Leukemic blasts in R/R AML frequently co-express CD33 and CLL1, while sparing normal hematopoietic stem cells, making them rational targets for chimeric antigen receptor (CAR) T-cell therapy.

This phase I, single-arm, open-label study evaluates ICG415 CAR-T Cells in patients with R/R AML. After leukapheresis and ex vivo modification, patients receive a single CAR-T cell infusion following lymphodepleting chemotherapy with fludarabine and cyclophosphamide. Primary objectives are safety and tolerability, including dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), and neurological events. Secondary objectives include response rate (CR/CRi/PR), minimal residual disease (MRD) negativity, progression-free survival (PFS), and overall survival (OS).

All participants will be followed for up to 24 months with regular clinical, laboratory, and imaging evaluations to monitor both treatment efficacy and potential complications.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • Acute Myeloid Leukemia
  • AML
  • Leukemia
  • Acute Leukemia
  • Myeloid Leukemia
  • CAR-T
  • Cellular Therapy
  • CD33-CLL1 CAR-T
  • Relapsed or Refractory
  • R/R AML
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written approved by IRB/IEC obtained from subject or legally authorized representative prior to any screening procedures.
  2. Age ≥ 18 years and ≤ 70 years at the time of informed consent signing.
  3. Diagnosis of acute myeloid leukemia (AML) per 2022 WHO Classification, meeting criteria for (R/R) AML as defined in the Chinese Guidelines for the Diagnosis and Management of Relapsed/Refractory Acute Myeloid Leukemia (2023 Edition): Relapsed AML: Reappearance of leukemic blasts in peripheral blood, bone marrow blasts ≥5%, or extramedullary leukemic infiltration after complete remission (CR). Refractory AML: failure to achieve CR after two cycles of standard induction chemotherapy; early relapse within 12 months post-CR; late relapse with salvage chemotherapy resistance; ≥2 disease relapses or persistent extramedullary disease.
  4. Bone marrow leukemic blasts positive for both CLL-1 and CD33 by flow cytometry.
  5. If circulating blasts are detectable at screening, tumor cell surface immunophenotype must be CD4 and CD8 double-negative by flow cytometry.
  6. performance status 0-2.
  7. Expected overall survival > 3 months.
  8. Females of : negative serum pregnancy test and effective for 1 year post-infusion. Males of : effective barrier contraception for 1 year post-infusion and no sperm donation within 1 year after infusion.

Exclusion criteria

Exclusion Criteria:

  1. Prior receipt of CAR-T cell therapy or other genetically modified cell therapy prior to .
  2. Severe major organ dysfunction: Renal: \< 50 mL/min (); Hepatic: /AST > 3 × (>5×ULN if disease-related), total > 2 × ULN (>3×ULN for Gilbert syndrome); Cardiac: \< 50%, room air SpO₂ \<94%, uncontrolled severe cardiac disease.
  3. Active uncontrolled infection: positive /HBV-DNA, active positivity, positive, positive syphilis antibody, active uncontrolled EBV or CMV viremia.
  4. Unstable severe systemic disease requiring continuous medication.
  5. Grade >2 bleeding within 30 days before screening or chronic long-term anticoagulant treatment.
  6. Uncontrolled life-threatening bacterial, fungal or viral infection.
  7. Non-leukemic central nervous system organic disease or active CNS-2/CNS-3 leukemia; previously treated and resolved CNS leukemia is permitted.
  8. Concurrent other malignant tumor except cured in-situ carcinoma or with ≥5 years continuous complete remission.
  9. within 30 days before screening or planned within 3 months after CAR-T infusion.
  10. Received any other medicinal product within 3 months prior to ICF signature.
  11. hematopoietic stem cell transplantation within 6 months before screening.
  12. Pregnant or breastfeeding women.
  13. Suicidal tendency, ongoing alcohol or illicit drug dependence.
  14. Known to investigational product, or concomitant drugs.
  15. Any other condition judged inappropriate for trial entry by investigator.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Single Arm, Anti-CD33-CLL1 CAR-T (ICG415) for Relapsed or Refractory AML

    Biological: Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide

Interventions

  • BiologicalAnti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide

    Anti-CD33, Anti-CLL1 Compound CAR-T Cells

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLTs)

    DLTs assessed according to the protocol-defined criteria.

    Time frame: Within 28 days after ICG415 CAR-T cell infusion

  2. Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)

    Frequency and severity of TEAEs graded by NCI-CTCAE Version 5.0, including changes from baseline in vital signs, physical examination, 12-lead ECG, and clinical laboratory parameters (complete blood count, urinalysis, blood chemistry, coagulation function, etc.).

    Time frame: From first dose through 24 months post infusion

Secondary outcomes

  1. Objective Response Rate (ORR) at Months 1, 3, and 6

    ORR defined as proportion of subjects achieving complete remission (CR), complete remission with incomplete count recovery (CRi), or complete remission with partial hematological recovery (CRh) per response criteria.

    Time frame: Month 1, Month 3, Month 6

  2. Rates of CR, CRi, and PR at Year 1 and Year 2

    Proportion of subjects achieving complete remission (CR), complete remission with incomplete count recovery (CRi), and partial remission (PR) at 1 and 2 years post infusion.

    Time frame: Year 1, Year 2

  3. Cumulative Incidence of Relapse (CIR) at Year 1 and Year 2

    Cumulative incidence of disease relapse at 1 and 2 years after CAR-T cell infusion.

    Time frame: Year 1, Year 2

  4. Duration of Response (DOR)

    Time from first objective response (CR, CRi, or CRh) to relapse or death, whichever occurs first.

    Time frame: From first documented response to disease relapse or death from any cause, assessed up to 24 months

  5. Progression-Free Survival (PFS)

    Time from ICG415 infusion to disease progression (relapse or treatment failure) or death from any cause.

    Time frame: From date of infusion to disease progression or death from any cause, assessed up to 24 months

  6. Overall Survival (OS)

    Time from ICG415 infusion to death from any cause.

    Time frame: From date of infusion to death from any cause, assessed up to 24 months

  7. Event-Free Survival (EFS)

    Time from ICG415 infusion to any event including lack of response, disease relapse, or death from any cause.

    Time frame: From date of infusion to any treatment failure, relapse, or death, assessed up to 24 months

  8. CAR-T Cell Kinetics - Persistence over Time

    Number and duration of detectable CAR-T cells in peripheral blood. Testing stops after two consecutive negative results.

    Time frame: Days 0, 4, 7, 14, 21, 28; Months 2, 3, 6, 9, 12, 18, 24

  9. Cytokine Level Changes

    Changes in serum cytokine levels including IL-6, IL-10, IL-15, TNF-α, and IFN-γ.

    Time frame: Days 0, 7, 14, 21, 28; Months 2, 3, 6

  10. Peripheral Blood Lymphocyte Subset Changes

    Changes in lymphocyte subsets including T cells, B cells, NK cells, and CD4/CD8 ratio measured by flow cytometry.

    Time frame: Days 0, 7, 14, 21, 28; Months 2, 3, 6

  11. Anti-Drug Antibody (ADA) Levels

    Incidence and titers of anti-drug antibodies (ADA) against ICG415 CAR-T cells.

    Time frame: Day 28; Months 3, 6, 12

07

Study locations

2 of 2 sites recruiting
  • Jiangxi Provincial People's Hospital (Participating Site)
    Nanchang, Jiangxi 330006, China
    Recruiting
  • The First Affiliated Hospital of Nanchang University (Lead Site)
    Nanchang, Jiangxi 330006, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 182 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 24 months is below that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2026
First posted
Jun 25, 2026
StartActual
Jun 10, 2026
Primary completionEst.
Jul 4, 2028
CompletionEst.
Jul 4, 2029
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07668557
Lead sponsor
iCell Gene Therapeutics
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jun 10, 2026
Primary completion
Jul 4, 2028 (estimated)
Completion
Jul 4, 2029 (estimated)
Last update
Jun 25, 2026

Study contacts

Yu Min
Contact
625668742@qq.com
+86 150 7902 9006
Li Fei
Contact
yx021021@sina.com
+86 139 7003 8386

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion